Abstract
The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a frequent cause of hyponatremia that presents substantial management challenges in clinical settings. Despite a range of treatment options, including fluid restriction, demeclocycline, and vasopressin antagonists, urea remains underutilized, particularly in North America, despite its well-documented efficacy, safety, and cost-effectiveness. Urea corrects hyponatremia by promoting osmotic diuresis without causing significant fluid shifts, making it an ideal treatment for both acute and chronic SIADH. Comparative studies have demonstrated urea's effectiveness, particularly in contrast to vasopressin antagonists, which are costly and pose risks such as hepatotoxicity and rapid sodium overcorrection. However, barriers to urea's utilization include limited clinician familiarity, lack of advocacy in guidelines, and patient adherence issues due to its unpalatable taste, although flavored formulations now address this issue. Increased awareness, training, and guideline inclusion could promote urea as a viable, primary treatment for SIADH. This editorial advocates for the expanded adoption of urea in clinical practice to enhance patient outcomes, especially in resource-limited settings where high-cost treatments may not be feasible.